Widespread closure of HIV prevention and care services places youth at higher risk during the COVID-19 pandemic.

BACKGROUND: Central to measuring the impact of the COVID-19 pandemic on HIV is understanding the role of loss of access to essential HIV prevention and care services created by clinic and community-based organization closures. In this paper, we use a comprehensive list of HIV prevention services in four corridors of the US heavily impacted by HIV, developed as part of a large RCT, to illustrate the potential impact of service closure on LGBTQ+ youth. METHODS: We identified and mapped LGBTQ+ friendly services offering at least one of the following HIV-related services: HIV testing; STI testing; PrEP/PEP; HIV treatment and care; and other HIV-related services in 109 counties across four major interstate corridors heavily affected by HIV US Census regions: Pacific (San Francisco, CA to San Diego, CA); South-Atlantic (Washington, DC to Atlanta, GA); East-North-Central (Chicago, IL to Detroit, MI); and East-South-Central (Memphis, TN to New Orleans, LA). RESULTS: There were a total of 831 LGBTQ+ youth-friendly HIV service providers across the 109 counties. There was a range of LGBTQ+ youth-friendly HIV-service provider availability across counties (range: 0-14.33 per 10,000 youth aged 13-24 (IQR: 2.13), median: 1.09); 9 (8.26%) analyzed counties did not have any LGBTQ+ youth-friendly HIV service providers. The Pearson correlation coefficient for the correlation between county HIV prevalence and LGBTQ+ youth-friendly HIV service provider density was 0.16 (p = 0.09), suggesting only a small, non-statistically significant linear relationship between a county's available LGBTQ+ youth-friendly HIV service providers and their HIV burden. CONCLUSIONS: As the COVID-19 pandemic continues, we must find novel, affordable ways to continue to provide sexual health, mental health and other support services to LGBTQ+ youth.

Perceived impacts of the COVID-19 pandemic on cannabis-using emerging adults.

Cannabis-using youth are a large epidemiologic subgroup whose age and smoking-related risks underscore the importance of examining the impact of the COVID-19 pandemic in this population. Within a clinical trial (n = 36 received an intervention prior to data collection reported herein), we surveyed cannabis-using emerging adults (ages 18-25) about perceived COVID-19 impacts. Participants (n = 141) reporting weekly cannabis use (M = 18.6 use days in the past 30) were enrolled and completed online surveys as part of either their baseline or 3 month assessment. COVID-19-related measures included symptoms, substance use, mood, etc. Participants were 57% female (mean age = 21, standard deviation = 2.2), with 21% Hispanic/Latinx, 70% White, 20% Black/African American, and 10% of other races. Most participants (86%) reported quarantine/self-isolation (M = 59 days). Several had COVID-19 symptoms (16%), but none reported testing COVID-19 positive. Many respondents felt their cannabis use (35%-50%, across consumption methods) and negative emotions (e.g., loneliness, stress, and depression; 69.5%, 69.5%, and 61.8%, respectively) increased. They reported decreased in-person socialization (90.8%) and job losses (23.4%). Reports of increased cannabis smoking were associated with increased negative emotions. On an open-response item, employment/finances and social isolation were frequently named negative impacts (33.3% and 29.4%, respectively). Although cannabis-using emerging adults' reports of increases in cannabis use, coupled with mental health symptoms and social isolation, are concerning, the full impact of the pandemic on their health and well-being remains unknown. Future studies examining the relationship between social isolation, mental health, and cannabis use among young people are needed.

COVID-19 Vaccine Acceptance among an Online Sample of Sexual and Gender Minority Men and Transgender Women.

Sexual and gender minority (SGM) populations are particularly vulnerable to poor COVID-19 outcomes and are more likely to experience stigma and medical mistrust that may impact COVID-19 vaccine acceptance. This study examined the prevalence of COVID testing and diagnosis and assessed COVID-19 vaccine acceptance among a large sample of SGM. Participants were recruited as part of an online cross-sectional study focused on an HIV biomedical prevention technology willingness in the United States at increased risk for HIV sero-conversion. Multivariate linear analysis was conducted to examine COVID-19 vaccine acceptance. The study sample included 1350 predominately gay (61.6%), Black (57.9%), cis-gender (95.7%) males with a mean age of 32.9 years. Medical mistrust and social concern regarding COVID-19 vaccine stigma were significantly associated with decreased COVID-19 vaccine acceptance, and altruism was significantly associated with increased vaccine acceptance. Black participants were significantly less likely to accept a COVID-19 vaccine, and Asian participants were significantly more likely to accept a vaccine, compared to White peers. As the planning of COVID-19 vaccine rollout efforts is conceptualized and designed, these data may inform equitable implementation strategies and prevent worsening health inequities among SGM populations.

Toward a New Framework for Equity in Epidemic Allocations: Implications of HIV-Prevention-Allocation Misalignment

Social stigma inhibits provision and uptake of HIV prevention and care;experiences and anticipation of stigma in health care settings are associated with lower rates of HIV testing, preexposure prophylaxis uptake, retention in care, and antiretroviral therapy adherence. [...]relying solely on biomedical HIV prevention for young Black and Latinx gay and bisexual men and transwomen will not constitute a sufficient response to their needs. In response, local researchers collaborated with local sexual and gender minority youths of color to develop, implement, and evaluate a multilevel HIV-prevention and care intervention.3 The Pennsylvania Department of Health and the state's HIV Planning Group, whose composition has robustly included most-at-risk populations empowered to identify priority populations and recommend resource allocations, supported and promoted the project for statewide scale-up. Emerging research incorporating wraparound clinical harm reduction4 and intersectional stigma reduction5 into biomedical HIV prevention shows promise. Because of their complexity, such interventions are difficult to operationalize, field, and consolidate into cost-per-person metrics;for these reasons, multilevel, social determinants-based interventions are excluded from allocation models provided. The proposed EqEA framework may help achieve Ending the HIV Epidemic endpoints and offers insights for other infectious diseases, such as directing COVID-19 prevention resources to minority communities wherein SARSCoV-2 is exacting a disproportionately lethal toll and federal aid formulas for hospitals have large-scale racial biases.7 Adopting equitable allocation strategies will ensure that resources do not remain woefully misaligned and our systems do not exacerbate the welldefined shortcomings of decades of efforts. >4jPH CORRESPONDENCE Correspondence should be sent to M. Reuel Friedman, PhD, PO Box 7319, Pittsburgh, PA 15213 (e-mail: mrf9@pitt.edu).